Powder: -20°C for 3 years | In solvent: -80°C for 1 year
5-Hydroxy-1-methylhydantoin (HD-003) 是一种可能用于治疗肾衰竭的抗氧化剂。它是肌酐代谢物,是一种羟基自由基清除剂,此前已显示通过抑制大鼠慢性肾病的进展来提供肾脏保护。 它是一种新型抗氧化药物,可完全抑制 B2-激肽受体(B2KR) 对 VSMC 中高葡萄糖 (25 mM) 刺激的反应,并且还显示可减弱 BK 对 VSMC 重塑的影响。它抑制 BK 诱导的 MAPK 磷酸化增加并减弱 VSMC 中结缔组织生长因子 (CTGF) 蛋白水平的增加。这些研究结果表明,它可能通过其抗氧化特性赋予血管保护免受高葡萄糖浓度和 BK 刺激以改善血管损伤和重塑。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 25,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,890 | 现货 |
产品描述 | 5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties. |
别名 | HD-003, HD003, 5-羟基-1-甲基咪唑啉-2,4-二酮, NZ419, NZ-419, HD 003, NZ 419 |
分子量 | 130.1 |
分子式 | C4H6N2O3 |
CAS No. | 84210-26-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (525.85 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 7.6864 mL | 38.432 mL | 76.864 mL | 192.1599 mL |
5 mM | 1.5373 mL | 7.6864 mL | 15.3728 mL | 38.432 mL | |
10 mM | 0.7686 mL | 3.8432 mL | 7.6864 mL | 19.216 mL | |
20 mM | 0.3843 mL | 1.9216 mL | 3.8432 mL | 9.608 mL | |
50 mM | 0.1537 mL | 0.7686 mL | 1.5373 mL | 3.8432 mL | |
100 mM | 0.0769 mL | 0.3843 mL | 0.7686 mL | 1.9216 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
5-Hydroxy-1-methylhydantoin 84210-26-4 GPCR/G Protein Bradykinin Receptor 5Hydroxy1methylhydantoin HD-003 HD003 5-羟基-1-甲基咪唑啉-2,4-二酮 NZ419 NZ-419 HD 003 NZ 419 5 Hydroxy 1 methylhydantoin Inhibitor inhibitor inhibit